skip to content


AAAS Science & Human Rights Coalition: 2021 Student Essay Competition Winner!

9 November 2021

We would like to congratulate PhD student Marco Travaglio for winning this year’s American Association for the Advancement of Science (AAAS): Science and Human Rights Coalition Student Essay Competition! This competition encourages participants to explore the intersections between human rights and science. Marco's essay...

Read more

Life sciences have key role in developing climate change solutions

26 October 2021

The MRC Toxicology Unit was represented in an EMBL-organised international expert workshop this July, the outcomes of which are discussed in the White Paper "Harnessing molecular biology to accelerate the Green Recovery". Read the full press release here .

Read more

New paper published in Nature: Bioaccumulation of therapeutic drugs by human gut bacteria

15 September 2021

Common medications can accumulate in gut bacteria, altering bacterial function and potentially reducing the medications’ effectiveness. This study started as a collaborative project at EMBL Heidelberg and was concluded in the group of Kiran Patil after his move to the MRC Toxiciology Unit in Cambridge. Read the full...

Read more

New paper published in Nature Communications today: The pathogenesis of mesothelioma is driven by a dysregulated translatome

13 August 2021

Mesothelioma cancer patients may benefit from new research that sheds light onto the reason behind the growth of these tumour cells which, unlike most cancers, have no oncogenic drivers. Scientists from the MRC Toxicology Unit (University of Cambridge) and the CRUK Beatson Institute (University of Glasgow) worked on the...

Read more

MRC Toxicology Unit Semi-finalists - Postdoc Business Plan Competition

3 August 2021

Congratulations to Gavin D. Garland and Aristedis Sfakianos who have made it through to the semi-finals of the 2021 Chris Abell Postdoc Business Plan competition! Find more information about the competition, semi-finalists and prizes here:

Read more

Dr Kiran Patil has been appointed as Deputy Editor for the open access journal: 'PLOS Computational Biology'

23 June 2021

This open access journal explores the " application of computational methods among disparate areas of biology" (PLOS Computaional Biology: Journal Information ). Editorial Board: PLOS Computational Biology: A Peer-Reviewed Open-Access Journal

Read more

Nature Communications featured article: Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

1 March 2021

A recently publised article from Dr. James Thaventhiran's group about the potential treatment effect of remedesvir in COVID-19 patients was chosen as a featured paper by Nature Communiactions. The scientific achivement is highlighted under the topic of "Microbiology and Infectious diseases" in the journal's January issue .

Read more

Cryo-EM structural analysis reveals Caspase-8 catalytic domain architecture for co-ordinated control of cell fate

17 February 2021

Marion MacFarlane, MRC Investigator and Deputy Director at the MRC Toxicology Unit is the senior author of a new study published in Nature Communications which reveals how ‘Cryo-EM structural analysis of FADD:Caspase-8 complexes defines the catalytic dimer architecture for co-ordinated control of cell fate’. “The core FADD...

Read more

Cooperation is key to success in microbial communities

12 January 2021

Dr Kiran Patil, Director of Research at the MRC Toxicology Unit is the senior author of a new study which shows how cooperation among bacterial species allows them to thrive as a community. This research is from the MRC Toxicology Unit at the University of Cambridge and the European Molecular Biology Laboratory (EMBL). "If...

Read more

Remdesivir likely to be highly effective antiviral against SARS-CoV-2

14 December 2020

The drug remdesivir is likely to be a highly effective antiviral against SARS-CoV-2, according to a new study by a team of UK scientists. Writing in Nature Communications, the researchers describe giving the drug to a patient with COVID-19 and a rare immune disorder, and observing a dramatic improvement in his symptoms and...

Read more